Pharmacogenetics of Psychiatric Diseases

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: closed (20 October 2024) | Viewed by 715

Special Issue Editor


E-Mail Website
Guest Editor
Unit for Psychiatric Research, Psychiatry, Aalborg University Hospital, DK-9100 Aalborg, Denmark
Interests: pharmacogenetics; precision medicine; psychiatry; genetic markers; rare variants; PRS; molecular pathway analysis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pharmacogenetics holds promise for a near Copernican revolution in psychiatry, where the current guideline-based, trial-and-error strategy has been known to lead to periods of untreated disorders, poor compliance, and various side effects. Pharmacogenetics, moreover, holds the potential to contribute to scientific development by allowing precision medicine to become the common treatment strategy in hospitals. The relevance of this field has been supported by emerging international guidelines in pharmacogenetics. However, implementable results, especially in the field of pharmacodynamics, currently lag behind expectations. There are numerous internationally coordinated initiatives underway to remove obstacles facing the application of pharmacogenetics in psychiatry. Nevertheless, the clinical diversity in therapy outcomes that has been found can only be partially explained by the validated pharmacogenomic markers that are already in place. It is necessary, therefore, to conduct additional research.

Given this knowledge, original research, reviews, and creative means of covering a variety of pharmacogenetics-related subjects in psychiatry are welcome in this Special Issue. The use of pharmacogenetics in clinical practice, the development of legislative tools and infrastructure related to pharmacogenetics, the search for novel pharmacogenetic markers specific to psychiatric treatments, the importance of epigenetics and rare genetic variants in pharmacogenetics, and innovative protocols for pharmacogenetic research are just a few of the subjects welcome.

Dr. Antonio Drago
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacogenetics
  • precision medicine
  • psychiatry
  • genetic markers
  • rare variants
  • PRS
  • molecular pathway analysis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 17803 KiB  
Article
Differential Expression of tRNA-Derived Small RNA Markers of Antidepressant Response and Functional Forecast of Duloxetine in MDD Patients
by Xiaoyan Wang, Ming Gao, Jing Song, Miaolong Li, Yu Chen, Yingfang Lv, Wei Jia and Bingbing Wan
Genes 2025, 16(2), 162; https://doi.org/10.3390/genes16020162 - 27 Jan 2025
Viewed by 436
Abstract
Background/Objectives: Duloxetine, despite being a leading treatment option for major depressive disorder (MDD), exhibits a relatively low adequate response rate when used as a monotherapy, and the fundamental molecular mechanisms remain largely elusive. tRNA-derived small RNA (tsRNA) is a particularly interesting and new [...] Read more.
Background/Objectives: Duloxetine, despite being a leading treatment option for major depressive disorder (MDD), exhibits a relatively low adequate response rate when used as a monotherapy, and the fundamental molecular mechanisms remain largely elusive. tRNA-derived small RNA (tsRNA) is a particularly interesting and new class of molecules that is becoming increasingly noticeable for investigation. Methods: We integrated small RNA sequencing with bioinformatics approaches to dissect the expression profiles of tsRNAs and decipher their functional roles post-duloxetine treatment. Subsequently, molecular docking experiments were carried out to validate the potential functions. Results: Ten tsRNAs significantly changed in the duloxetine response group after an 8-week therapy. Correlation analyses revealed that these tsRNAs predominantly interacted with miRNAs across multiple biological pathways and processes, such as the ECM-receptor interaction and B cell activation. Molecular docking analysis corroborated the binding capabilities of duloxetine with key proteins associated with ECM1 and BAFF, respectively. Conclusions: The identified changes in tsRNAs can precisely mirror the response of duloxetine in MDD treatment, offering novel insights into the underlying mechanisms of duloxetine action. Full article
(This article belongs to the Special Issue Pharmacogenetics of Psychiatric Diseases)
Show Figures

Figure 1

Back to TopTop